159 related articles for article (PubMed ID: 37819239)
1. Immune Cell Abundance and T-cell Receptor Landscapes Suggest New Patient Stratification Strategies in Head and Neck Squamous Cell Carcinoma.
Secrier M; McGrath L; Ng F; Gulati S; Raymond A; Nuttall BRB; Berthe J; Jones EV; Sidders BS; Galon J; Barrett JC; Angell HK
Cancer Res Commun; 2023 Oct; 3(10):2133-2145. PubMed ID: 37819239
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral tertiary lymphoid structures promote patient survival and immunotherapy response in head neck squamous cell carcinoma.
Liu Z; Meng X; Tang X; Zou W; He Y
Cancer Immunol Immunother; 2023 Jun; 72(6):1505-1521. PubMed ID: 36481914
[TBL] [Abstract][Full Text] [Related]
3. Compartmentalized spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma identifies immune checkpoint molecules and tumor necrosis factor receptor superfamily members as biomarkers of response to immunotherapy.
Sadeghirad H; Liu N; Monkman J; Ma N; Cheikh BB; Jhaveri N; Tan CW; Warkiani ME; Adams MN; Nguyen Q; Ladwa R; Braubach O; O'Byrne K; Davis M; Hughes BGM; Kulasinghe A
Front Immunol; 2023; 14():1135489. PubMed ID: 37153589
[TBL] [Abstract][Full Text] [Related]
4. Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts.
Woolaver RA; Wang X; Krinsky AL; Waschke BC; Chen SMY; Popolizio V; Nicklawsky AG; Gao D; Chen Z; Jimeno A; Wang XJ; Wang JH
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33414263
[TBL] [Abstract][Full Text] [Related]
5. Uncovering immune checkpoint heterogeneity in oral squamous cell carcinoma using single cell RNA-sequencing data highlights three subgroups of patients with distinct immune phenotypes.
Le Meitour Y; Foy JP; Guinand M; Michon L; Karabajakian A; Fayette J; Saintigny P; Mahtouk K
Oral Oncol; 2024 Feb; 149():106680. PubMed ID: 38218022
[TBL] [Abstract][Full Text] [Related]
6. Tertiary Lymphoid Structure Raises Survival and Immunotherapy in HPV
Li H; Zhu SW; Zhou JJ; Chen DR; Liu J; Wu ZZ; Wang WY; Zhang MJ; Sun ZJ
J Dent Res; 2023 Jun; 102(6):678-688. PubMed ID: 36883630
[TBL] [Abstract][Full Text] [Related]
7. Dynamic profiling of immune microenvironment during anti-PD-1 immunotherapy for head and neck squamous cell carcinoma: the IPRICE study.
Hélène C; Conrad O; Pflumio C; Borel C; Voegelin M; Bernard A; Schultz P; Onea MA; Jung A; Martin S; Burgy M
BMC Cancer; 2023 Dec; 23(1):1209. PubMed ID: 38066522
[TBL] [Abstract][Full Text] [Related]
8. Bioinformatic analysis identifies HPV-related tumor microenvironment remodeling prognostic biomarkers in head and neck squamous cell carcinoma.
Zhou Q; Yuan O; Cui H; Hu T; Xiao GG; Wei J; Zhang H; Wu C
Front Cell Infect Microbiol; 2022; 12():1007950. PubMed ID: 36425786
[TBL] [Abstract][Full Text] [Related]
9. A meta-validated immune infiltration-related gene model predicts prognosis and immunotherapy sensitivity in HNSCC.
Ding Y; Chu L; Cao Q; Lei H; Li X; Zhuang Q
BMC Cancer; 2023 Jan; 23(1):45. PubMed ID: 36639648
[TBL] [Abstract][Full Text] [Related]
10. Single-cell RNA sequencing reveals TCR
Jiang Y; Zhang S; Tang L; Li R; Zhai J; Luo S; Peng Y; Chen X; Wei L
Front Immunol; 2022; 13():1030222. PubMed ID: 36389736
[TBL] [Abstract][Full Text] [Related]
11. Constructing heterogeneous single-cell landscape and identifying microenvironment molecular characteristics of primary and lymphatic metastatic head and neck squamous cell carcinoma.
Zhang J; Liu Y; Xia L; Zhen J; Gao J; Atsushi T
Comput Biol Med; 2023 Oct; 165():107459. PubMed ID: 37713790
[TBL] [Abstract][Full Text] [Related]
12. DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma.
Starzer AM; Heller G; Tomasich E; Melchardt T; Feldmann K; Hatziioannou T; Traint S; Minichsdorfer C; Schwarz-Nemec U; Nackenhorst M; Müllauer L; Preusser M; Berghoff AS; Fuereder T
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338086
[TBL] [Abstract][Full Text] [Related]
13. APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma.
Faden DL; Ding F; Lin Y; Zhai S; Kuo F; Chan TA; Morris LG; Ferris RL
Oral Oncol; 2019 Sep; 96():140-147. PubMed ID: 31422205
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas.
Succaria F; Kvistborg P; Stein JE; Engle EL; McMiller TL; Rooper LM; Thompson E; Berger AE; van den Brekel M; Zuur CL; Haanen J; Topalian SL; Taube JM
Cancer Immunol Immunother; 2021 May; 70(5):1227-1237. PubMed ID: 33125511
[TBL] [Abstract][Full Text] [Related]
15. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
[TBL] [Abstract][Full Text] [Related]
16. The prognostic impact of the immune signature in head and neck squamous cell carcinoma.
Baysal H; Siozopoulou V; Zaryouh H; Hermans C; Lau HW; Lambrechts H; Fransen E; De Pauw I; Jacobs J; Peeters M; Pauwels P; Vermorken JB; Smits E; Lardon F; De Waele J; Wouters A
Front Immunol; 2022; 13():1001161. PubMed ID: 36268020
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive analysis of immune cell enrichment in the tumor microenvironment of head and neck squamous cell carcinoma.
Mito I; Takahashi H; Kawabata-Iwakawa R; Ida S; Tada H; Chikamatsu K
Sci Rep; 2021 Aug; 11(1):16134. PubMed ID: 34373557
[TBL] [Abstract][Full Text] [Related]
18. Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy.
Chen YP; Wang YQ; Lv JW; Li YQ; Chua MLK; Le QT; Lee N; Colevas AD; Seiwert T; Hayes DN; Riaz N; Vermorken JB; O'Sullivan B; He QM; Yang XJ; Tang LL; Mao YP; Sun Y; Liu N; Ma J
Ann Oncol; 2019 Jan; 30(1):68-75. PubMed ID: 30407504
[TBL] [Abstract][Full Text] [Related]
19. Molecularly targeted agents and immunotherapy for the treatment of head and neck squamous cell cancer (HNSCC).
Azoury SC; Gilmore RC; Shukla V
Discov Med; 2016 Jun; 21(118):507-16. PubMed ID: 27448787
[TBL] [Abstract][Full Text] [Related]
20.
Chen L; Lin J; Lan B; Xiong J; Wen Y; Chen Y; Chen CB
Comput Math Methods Med; 2022; 2022():5851755. PubMed ID: 36510584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
